IN2014DN09392A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09392A
IN2014DN09392A IN9392DEN2014A IN2014DN09392A IN 2014DN09392 A IN2014DN09392 A IN 2014DN09392A IN 9392DEN2014 A IN9392DEN2014 A IN 9392DEN2014A IN 2014DN09392 A IN2014DN09392 A IN 2014DN09392A
Authority
IN
India
Prior art keywords
compounds
essentially pure
xxv
stimulating
formulas
Prior art date
Application number
Other languages
English (en)
Inventor
Walter A Shaw
Stephen W Burgess
Shengrong Li
David T Hickman
Maria Pilar Lopez-Deber
Original Assignee
Avanti Polar Lipids Inc
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanti Polar Lipids Inc, Ac Immune Sa filed Critical Avanti Polar Lipids Inc
Publication of IN2014DN09392A publication Critical patent/IN2014DN09392A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0007Nervous system antigens; Prions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06Fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN9392DEN2014 2012-04-12 2013-04-12 IN2014DN09392A (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623393P 2012-04-12 2012-04-12
US13/842,424 US9241988B2 (en) 2012-04-12 2013-03-15 Disaccharide synthetic lipid compounds and uses thereof
PCT/US2013/036425 WO2013155448A1 (en) 2012-04-12 2013-04-12 Disaccharide synthetic lipid compounds and uses thereof

Publications (1)

Publication Number Publication Date
IN2014DN09392A true IN2014DN09392A (enExample) 2015-07-17

Family

ID=49325307

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9392DEN2014 IN2014DN09392A (enExample) 2012-04-12 2013-04-12

Country Status (9)

Country Link
US (2) US9241988B2 (enExample)
EP (2) EP3674309B1 (enExample)
JP (3) JP6271510B2 (enExample)
CN (2) CN107412766A (enExample)
CA (1) CA2870008C (enExample)
DK (1) DK3674309T3 (enExample)
ES (2) ES2992314T3 (enExample)
IN (1) IN2014DN09392A (enExample)
WO (1) WO2013155448A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101378872B1 (ko) 2006-09-26 2014-04-11 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 합성 애주번트를 함유하는 백신 조성물
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
CN107073105B (zh) * 2014-09-12 2021-04-06 巴斯特威尔控股有限公司 用于提供含佐剂病毒体的方法及由此可获得的含佐剂病毒体
EP3069729A1 (en) * 2015-03-17 2016-09-21 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2016149417A1 (en) * 2015-03-17 2016-09-22 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
EP3849521A1 (en) 2018-09-14 2021-07-21 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
US12016885B2 (en) 2018-11-06 2024-06-25 Alsatech, Inc. Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
BR112022008761A2 (pt) 2019-11-22 2022-07-26 Glaxosmithkline Biologicals Sa Dosagem e administração de uma vacina de glicoconjugado de sacarídeo
US20230190920A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
EP4590402A1 (en) 2022-09-21 2025-07-30 Wisconsin Alumni Research Foundation Compositions and methods to enhance therapeutic efficacy of cancer therapies
WO2024151642A1 (en) * 2023-01-09 2024-07-18 University Of Maryland, Baltimore Engineered anti-nociceptive-los competitive tlr4 ligands and methods for treating pain while maintaining immunosufficiency
WO2026087792A1 (en) 2024-10-27 2026-04-30 Idorsia Pharmaceuticals Ltd Vaccine against klebsiella pneumoniae

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066794A (en) 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
GR860379B (en) * 1985-02-22 1986-06-11 Akzo Nv Novel disaccharide and trisaccharide derivatives of the lipid a type
JP2535048B2 (ja) 1988-02-29 1996-09-18 第一製薬株式会社 新規ジサッカライド誘導体及びその塩
JPH06206893A (ja) * 1992-09-07 1994-07-26 Suntory Ltd 新規なジサッカライド誘導体
AU679970B2 (en) 1993-09-07 1997-07-17 Suntory Limited Novel disaccharide derivative
JP3967769B2 (ja) * 1993-11-17 2007-08-29 オーエム・ファルマ グルコサミンジサッカライド、それらの製造法、それらを含む医薬組成物およびそれらの使用
JPH10152497A (ja) * 1996-09-30 1998-06-09 Otsuka Pharmaceut Factory Inc ヘリコバクター・ピロリのリピドa
HK1039072A1 (zh) * 1998-05-07 2002-04-12 科里克萨有限公司 佐剂组合物及其使用方法
AU763770B2 (en) * 1998-07-14 2003-07-31 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
AU780577B2 (en) * 1999-11-15 2005-04-07 Oncothyreon Inc. Synthetic Lipid-A analogs and uses thereof
WO2001090129A2 (en) * 2000-05-19 2001-11-29 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
CN1907289A (zh) * 2000-05-19 2007-02-07 科里克萨有限公司 用单糖和二糖类化合物预防和治疗传染病和其他疾病的方法
US20030031684A1 (en) * 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
WO2009035528A2 (en) * 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
KR101617895B1 (ko) * 2007-12-24 2016-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 재조합 rsv 항원
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof

Also Published As

Publication number Publication date
JP6764396B2 (ja) 2020-09-30
JP2020147579A (ja) 2020-09-17
CN107412766A (zh) 2017-12-01
JP6271510B2 (ja) 2018-01-31
JP2015512946A (ja) 2015-04-30
EP2836499B1 (en) 2020-02-26
JP7189906B2 (ja) 2022-12-14
EP3674309A1 (en) 2020-07-01
JP2018070652A (ja) 2018-05-10
WO2013155448A1 (en) 2013-10-17
US10143744B2 (en) 2018-12-04
US9241988B2 (en) 2016-01-26
DK3674309T3 (da) 2024-11-25
CN104470938B (zh) 2017-07-28
US20160136271A1 (en) 2016-05-19
EP2836499A1 (en) 2015-02-18
CA2870008A1 (en) 2013-10-17
CN104470938A (zh) 2015-03-25
ES2787876T3 (es) 2020-10-19
EP3674309B1 (en) 2024-09-11
US20130273149A1 (en) 2013-10-17
ES2992314T3 (es) 2024-12-11
CA2870008C (en) 2021-05-04
EP2836499A4 (en) 2015-11-25
HK1207383A1 (en) 2016-01-29

Similar Documents

Publication Publication Date Title
PH12016501151A1 (en) Nrf2 regulators
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
MX2016011898A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
PH12015502216A1 (en) Compositions and methods for improving the health of aquatic animals
EP3679785A3 (en) Methods and compositions for integration of an exogenous sequence within the genome of plants
PH12014502350A1 (en) Mixtures, methods and compositions pertaining to conductive materials
EA201290876A1 (ru) Композиции индуцированных дендритных клеток и их использование
GB0917002D0 (en) Improved shigella blebs
EP3725811A3 (en) Compositions for inhibiting masp-2 dependent complement activation
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MX360499B (es) Cepas microbianas, composiciones y metodos para incrementar el fosfato disponible para las plantas.
EP4480544A3 (en) Immunomodulatory compositions andmethods of use thereof
MX2021004211A (es) Composiciones vacuna.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
IN2014DN06104A (enExample)
MY190647A (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
MX348325B (es) Composicion que contiene galacto-oligosacarido y un metodo para producirla.
PH12017500836A1 (en) Transdermal formulations
MX2018011162A (es) Metodos de purificacion de colageno 7.
IN2014DN03298A (enExample)
SG10201900541QA (en) Derivatives of xanthone compounds
MX2016000313A (es) Estabilizadores de luz novedosos.
IN2014DN08412A (enExample)
IN2013MU03641A (enExample)
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth